Tristel's ULT disinfectant gains traction with Mayo Clinic study
By Josh White
Date: Wednesday 09 Apr 2025
(Sharecast News) - Tristel reported growing traction for its 'Tristel ULT' disinfection foam in North America on Wednesday, underpinned by positive feedback from leading healthcare institutions and steady sales growth.
The AIM-traded company highlighted the publication of a new case study from the Mayo Clinic, presented at the AORN Global Surgical Conference in Boston.
It said the study evaluated the use of Tristel ULT over a 90-day period involving 189 ultrasound probe reprocessing procedures by 11 staff members.
No surgical site infections were reported during the trial.
The study described the foam-based high-level disinfection (HLD) method as effective, efficient, and cost-saving, with benefits including reduced reprocessing time and less probe damage.
Tristel said the Mayo Clinic trial added to a growing body of US evidence supporting its chlorine dioxide-based technology, following its recognition in an updated ANSI/AAMI standard published in February.
It also built on a separate white paper released in May last year by US urologist Dr Matthew Allaway, which outlined the product's advantages in busy urology settings.
Tristel said sales of ULT in North America were continuing to grow in line with internal expectations, supported by increased adoption and usage within existing customer accounts.
As of the end of the third quarter, the product had been used in more than 200,000 disinfection procedures in the region during the current financial year.
"We are delighted to see such positive feedback on the use of Tristel ULT in clinical practice at the renowned Mayo Clinic," said chief executive officer Matt Sassone.
"As a leading US hospital, the Mayo Clinic pride themselves in excellence and are always seeking to adopt the best possible practices in infection control.
"To have them present this poster to the thousands of perioperative professionals who attend this conference is a great support to our plans to wider drive adoption in the US."
Sassone said the company was confident in its continued momentum across North America, and was looking forward to US revenues becoming substantial in the coming years.
"As Tristel ULT is manufactured in the United States by our partner, Parker Labs, we're confident that the newly announced tariffs will have no adverse impact on our pricing or sales performance in North America."
At 1227 BST, shares in Tristel were up 3.7% at 280p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN